I have believed for some time that ENMD 1198 was selected for development in order to provide Panzem's potential without it's bioavailability problems. This thought allows dropping future oncology development for Panzem without having to see any bad news.
The source of the company's confidence remains a critical curiousity in the face of future funding issues. Maybe we'll have some good news real soon now.
Market Data 
Markets 
AI
